Back

Specific therapy: tafamidis, acoramidis, what else?

28 November 2025 (11:56 - 12:08)
Organised by: Logo
Seminar Presentation Part of: SESSION IV - TTR-related Cardiac amyloidosis: therapeutic challenges (joint with HFA Cardiac Amyloidosis Committee) Pericardial Disease, Other Open Access M&PD Annual meeting 2025 WG on Myocardial and Pericardial Diseases

About the speaker

Photo
Mr Pablo Garcia Pavia

Iron Gate Majadahonda University Hospital, Madrid (Spain)

4 More presentations in this session

Presentation thumbnail
Heart failure therapies: focus on MRAs/K binders and SGLT2i
Doctor A. Porcari (Trieste, IT)
Presentation thumbnail
Real-world data
Doctor F. Cappelli (Florence, IT)
Slides
Presentation thumbnail
Stabilizers, Gene silencing/editing, Depletors: how can we select the best candidates?
Professor M. Emdin (Pisa, IT)
Presentation thumbnail
Lecture - Risk stratification in DCM/NDLVC
Professor P. Elliott (London, GB)
Slides

Access the full session

Session thumbnail
SESSION IV - TTR-related Cardiac amyloidosis: therapeutic challenges (joint with HFA Cardiac Amyloidosis Committee)

The Event

Event poster

M&PD Annual meeting 2025

28 November 2025 11:56 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Drugs
16 April 2023
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025
thumbnail
Congress Presentation
Exploring the wealth of long-term data for ATTR-CM management​
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources